Replies to post #762275 on NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Hope so too. Let me iterate something in your post:
"Moffitt Cancer Center named top ten cancer hospital in the world."

[XMaster2023]

Several entities are involved in the development and clinical trials of Anti-HER2/3 Dendritic Cell Vaccines:

* Northwest Biotherapeutics: This company is currently in Phase II clinical development of an Anti-HER2/HER3 Dendritic Cell Vaccine for metastatic brain tumors.
* H. Lee Moffitt Cancer Center & Research Institute: This institute is listed as the originator and active organization for a Dendritic Cell Vaccine. They are involved in multiple clinical trials related to HER2/3 targeting dendritic cell vaccines.
* IOZK Immuno-Oncology Center Cologne: This center conducted a Phase I clinical trial of an autologous dendritic cell vaccine against HER2.
* Various Research Institutions and Hospitals: Numerous clinical trials are being conducted at different locations, including Moffitt Cancer Center, Roswell Park Cancer Institute, and others. These trials involve collaborations between institutions and pharmaceutical companies.
It's important to note that while these entities are involved in the research and development, the specific manufacturer that would produce a commercially available Anti-HER2/3 DC Vaccine in the future would likely depend on the outcomes of these clinical trials and regulatory approvals.
General Information about Anti-HER2/3 DC Vaccines:
An anti-HER2/3 dendritic cell vaccine is a type of cancer vaccine that uses dendritic cells (a type of immune cell) to target and attack cancer cells that overexpress the HER2 and HER3 proteins. These proteins are often found in high levels in various cancers, including breast cancer and brain tumors.
How it works:
* Dendritic cells are obtained from the patient's blood.
* These cells are then "educated" in the laboratory to recognize HER2 and HER3 proteins. This is often done by exposing the dendritic cells to HER2/3 antigens.
* The activated dendritic cells are then injected back into the patient.
* These cells travel to the lymph nodes, where they present the HER2/3 antigens to other immune cells, such as cytotoxic T-lymphocytes (CTLs).
* This process stimulates a potent immune response, where the CTLs can recognize and destroy cancer cells expressing HER2 and HER3.
Clinical Trials:
Several clinical trials are currently underway to evaluate the safety and effectiveness of Anti-HER2/3 Dendritic Cell Vaccines for various cancers, including:
* Metastatic breast cancer that has spread to the brain (brain metastasis) or the lining of the brain and spinal cord (leptomeningeal disease).
* Triple-negative breast cancer.
* HER2-positive breast cancer.
* Glioblastoma (a type of brain cancer).
These trials are exploring different approaches, such as combining the vaccine with other immunotherapies like pembrolizumab or other targeted therapies. The results of these trials will help determine the potential role of Anti-HER2/3 DC vaccines in cancer treatment.